Skip to main content
. 2017 May 18;116(12):1558–1563. doi: 10.1038/bjc.2017.142

Figure 4.

Figure 4

Impact of CNS symptoms and steroids on intracranial PFS and OS. (A) The intracranial progression-free survival (PFS) was significantly lower in patients with symptomatic brain metastases than in asymptomatic patients: 2.7 vs 7.4 months (HR 1.95 (95% CI 1.05–3.63), P=0.0348). (B) Patients with symptomatic brain metastases had a shorter median survival than patients with asymptomatic metastases: 5.7 vs 13.0 months (HR 1.91 (95% CI 0.95–3.84), P=0.068). (C) Patients on corticosteroids had a shorter PFS than those not on corticosteroids: 3.2 vs 7.4 months (HR 1.72 (95% CI 0.93–3.17), P=0.081). (D) Patients on corticosteroids had a shorter OS than those not on corticosteroids: 4.8 vs 13.1 months (HR 2.06 (95% CI 1.04–4.11) P=0.039).